V. Gruenwald Et Al. , "An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy," EUROPEAN JOURNAL OF CANCER , vol.48, no.3, pp.324-332, 2012
Gruenwald, V. Et Al. 2012. An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. EUROPEAN JOURNAL OF CANCER , vol.48, no.3 , 324-332.
Gruenwald, V., Karakiewicz, P. I., Bavbek, S. E., Miller, K., Machiels, J., Lee, S., ... Larkin, J.(2012). An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. EUROPEAN JOURNAL OF CANCER , vol.48, no.3, 324-332.
Gruenwald, Viktor Et Al. "An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy," EUROPEAN JOURNAL OF CANCER , vol.48, no.3, 324-332, 2012
Gruenwald, Viktor Et Al. "An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy." EUROPEAN JOURNAL OF CANCER , vol.48, no.3, pp.324-332, 2012
Gruenwald, V. Et Al. (2012) . "An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy." EUROPEAN JOURNAL OF CANCER , vol.48, no.3, pp.324-332.
@article{article, author={Viktor Gruenwald Et Al. }, title={An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy}, journal={EUROPEAN JOURNAL OF CANCER}, year=2012, pages={324-332} }